![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 22, 19389-19395, May 31, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Hematology/Oncology, St. Jude
Children's Research Hospital, Memphis, Tennessee 38105
Received for publication, January 25, 2002, and in revised form, March 4, 2002
Phosphorylation of Thr-68 by the ataxia
telangiectasia-mutated is necessary for efficient activation of Chk2
when cells are exposed to ionizing radiation. By an unknown mechanism,
this initial event promotes additional autophosphorylation events
including modifications of Thr-383 and Thr-387, two amino acid residues located within the activation loop segment within the Chk2 catalytic domain. Chk2 and related kinases possess one or more
Forkhead-associated (FHA) domains that are phosphopeptide-binding
modules believed to be crucial for their checkpoint control activities.
We show that the Chk2 FHA domain is dispensable for Thr-68
phosphorylation but necessary for efficient autophosphorylation in
response to ionizing radiation. Phosphorylation of Thr-68 promotes
oligomerization of Chk2 by serving as a specific ligand for the FHA
domain of another Chk2 molecule. In addition, Chk2 phosphorylates its
own FHA domain, and this modification reduces its affinity for
Thr-68-phosphorylated Chk2. Thus, activation of Chk2 in irradiated
cells may occur through oligomerization of Chk2 via binding of the
Thr-68-phosphorylated region of one Chk2 to the FHA domain of another.
Oligomerization of Chk2 may therefore increase the efficiency of
trans-autophosphorylation resulting in the release of active Chk2
monomers that proceed to enforce checkpoint control in irradiated cells.
The maintenance of genomic integrity following DNA damage requires
the coordinated actions of DNA repair and cell cycle checkpoint control. The Chk2/hCds1 protein kinase is activated by DNA damage and
phosphorylates several known modulators of cell cycle control including
the tumor suppressor proteins, p53 and BRCA1, and Cdc25A phosphatase
(1-9). Mutations in the CHK2 gene have been identified in
human hereditary and sporadic cancers suggesting that
post-translational modifications mediated by Chk2 play important roles
in altering the activities of these checkpoint control proteins
(10-14). Therefore, exploring the mechanisms by which Chk2 activity is
regulated will enhance our understanding of the complex network of
signaling pathways that serve to limit tumor development.
Chk2 is a direct target and major effector of the
ATM1 kinase, a key regulator
of cell cycle checkpoint control in irradiated cells (for review see
Ref. 15). In response to ionizing radiation (IR) and double-stranded
DNA breaks, ATM phosphorylates Chk2 on Thr-68 within the amino-terminal
SQ/TQ-rich domain, and this event is necessary for efficient activation
of the Chk2 kinase (16-18). Recent evidence suggests that Chk2 is
phosphorylated on Thr-383 and Thr-387 in a phosphothreonine 68 (Thr(P)-68)-dependent manner (19). These residues are
located within the activation loop segment of Chk2 and therefore may be
Chk2 autophosphorylation sites that increase the specific activity of
the enzyme when modified (19, 20). This model is consistent with our
observations that a catalytic inactive Chk2 fails to exhibit
phosphorylation-dependent mobility shifts upon SDS-PAGE
even though clearly phosphorylated on Thr-68, suggesting that
additional phosphorylation events are dependent upon a functional Chk2
catalytic domain and necessary for full activation (18). How Thr-68
phosphorylation specifically leads to Chk2 autophosphorylation and
activation is currently unknown.
Additional clues as to how DNA damage-dependent Chk2
phosphorylation might be regulated are revealed through structural and biochemical studies of its two yeast homologues, Saccharomyces cerevisiae RAD53 and Schizosaccharomyces pombe Cds1. In
addition to an amino-terminal SQ/TQ-rich domain, Chk2-related kinases
like Cds1 and RAD53 contain one or two FHA
(forkhead-associated) domains (for
review see Ref. 15). Current structural and biochemical data indicate
that FHA domains mediate phosphospecific protein-protein interactions
and are thus considered important signaling moieties (21-24). This is
exemplified in RAD53, where the carboxyl-terminal FHA domain binds to
DNA damage-induced phosphorylated forms of RAD9, and this interaction
is required for DNA damage-induced checkpoint functions in budding
yeast (21). This interaction may also be crucial for enhancing RAD53
activity in DNA-damaged cells because phosphorylated RAD9 serves as a
scaffold for RAD53 binding via the RAD53 FHA domain and thereby
facilitates RAD53 trans-autophosphorylation and activation (25).
Therefore, based on the structural and functional similarities between
Chk2 and RAD53, the Chk2 FHA domain may play an important role in the
regulation of Chk2 activity in irradiated cells. The identification of
mutations within the FHA domain of Chk2 in several variant Li-Fraumeni
syndrome (LFS) families and sporadic cancers strengthens the concept
that this domain is important for Chk2 function (10, 11, 26).
It has been reported previously that the Chk2 FHA domain is required
for DNA damage-dependent Thr-68 phosphorylation and
activation of Chk2 (19). Thus far, only the LFS-associated mutations
(I157T or R145W) within the FHA domain have been characterized
as to their ability to be phosphorylated on Thr-68 and activated by IR.
Others have shown (27) that the I157T mutant is efficiently phosphorylated on Thr-68 and activated by IR suggesting that this mutation does not affect upstream signaling to Chk2. Unlike the I157T
mutant Chk2, the R145W mutant is poorly Thr-68-phosphorylated and
activated by IR consistent with this mutation abrogating Chk2 function
(19, 27). However, this mutant is also very unstable and may exist in a
large, inactive complex that renders it inaccessible to upstream
signaling cascades initiated by DNA damage (26, 27). Therefore, it is
difficult to interpret data obtained with the R145W mutant because it
is unclear whether this mutation solely affects FHA domain function or
induces a more drastic conformational change that alters the entire
structure of Chk2.
We created a series of defined mutations within the FHA domain of Chk2
to further address whether it is necessary for the activation of Chk2
by ATM. Individual point mutations of theoretical phosphopeptide-binding residues within the Chk2 FHA domain did not
alter the stability of the protein nor the ability of ATM to
phosphorylate Thr-68. Instead, these mutations negatively affected autophosphorylation. We also demonstrate that the FHA domain of Chk2
binds specifically to the SQ/TQ-rich region of Chk2 in a Thr(P)-68-dependent manner. This association in turn may
promote autophosphorylation at multiple sites including the FHA domain resulting in dissociation of this complex. Together, these data suggest
that Thr-68 phosphorylation by ATM promotes association of two or more
Chk2 molecules by enhancing the affinity of the SQ/TQ-rich domain of
one Chk2 molecule for the Chk2 FHA domain of another. Oligomer
formation may then facilitate trans-autophosphorylation and activation
of Chk2 in irradiated cells.
Antibodies--
Rabbit polyclonal antibodies (Zymed
Laboratories Inc.) specific to phospho-Thr-68 of Chk2 were raised
against a peptide containing ETVST(-PO4)QELYS and purified
using antigen peptide conjugated to Sepharose (Hartwell Center for
Bioinformatics and Biotechnology at St. Jude Children's Research
Hospital). Antibodies were further purified by passage through Thr-68
peptide (ETVSTQELYS)-Sepharose to deplete contaminating antibodies that
are reactive with Chk2 not phosphorylated at Thr-68. Commercial
antibodies used in this study included monoclonal anti-FLAG M5 (Sigma),
monoclonal anti-GST and c-Myc (Roche Molecular Biochemicals), and
polyclonal goat anti-Chk2 N-17 (Santa Cruz Biotechnology).
Cell Culture--
293T/17 and HCT-15 (which contains a
heterozygous R145W mutation within the FHA domain of Chk2 (10)) cells
were obtained from the American Type Culture Collection and grown in
Dulbecco's modified Eagle's media containing 10% fetal calf serum.
For retrovirus production, 293T/17 cells were co-transfected with
pBabe/puro FLAG Chk2 and the amphotropic pEQPAM3 packaging construct
using calcium phosphate. After 48 h, media were collected, and
HCT-15 cells were exposed three times to retrovirus in the presence of 4 µg/ml Polybrene. After 2 days, retrovirus-infected cells were selected in 10 µg/ml puromycin and used for the further
experimentation. Where indicated, cells were exposed to ionizing
radiation from a 137Cs source delivered at a dose rate of
~1.2 Gy/min.
Plasmid Constructs--
The pET-15b containing full-length wild
type (wt) and catalytic inactive (D368N) Chk2 (hsCds1) cDNAs were
kindly provided by H. Piwnica-Worms (28). pGEX-Chk2-(1-80) has been
described previously (18) and consists of the first 80 amino acids of Chk2 comprising the SQ/TQ-rich domain fused to GST. cDNA fragments containing the FHA domain (amino acids 60-225) or catalytic inactive kinase domain (amino acids 222-543, D368N) of Chk2 were amplified by
PCR and cloned into the pGEX4T-1 (Amersham Biosciences) and/or pET-28a
(Novagen). Site-directed mutagenesis of pSG5-FLAG Chk2 (18) was
performed by a two-step overlap PCR approach using oligonucleotide
primers containing the desired mutation and primers corresponding to
the 5' and 3' end of Chk2. FLAG-tagged wild type and mutant Chk2
cDNAs were excised from pSG5 and subcloned into the pBabe/puro
retrovirus vector. All oligonucleotide synthesis and plasmid sequence
analyses were performed by the Hartwell Center for Bioinformatics and
Biotechnology at St. Jude Children's Research Hospital.
Recombinant Protein Production--
Escherichia coli
BL21/DE3 cells were induced to express recombinant His6 or
GST-tagged proteins with 0.4 mM
isopropyl-1-thio-D-galactopyranoside overnight at 16 °C.
Cells expressing GST-tagged proteins were lysed in STE (150 mM NaCl, 50 mM Tris-HCl, pH 8, 1 mM
EDTA) plus 1 mM phenylmethylsulfonyl fluoride and 2%
Triton X-100. GST-tagged proteins were then bound to
glutathione-Sepharose beads (Sigma). Cells expressing
His6-tagged FHA or kinase domain were lysed in 50 mM NaH2PO4, pH 8.0, 10 mM imidazole, 300 mM NaCl, 0.3% Sarkosyl, and
protease inhibitors (1 mM phenylmethysulfonyl fluoride, 10 µg/ml aprotinin, 5 µg/ml pepstatin, and 5 µg/ml leupeptin).
Nonidet P-40 (0.6%) was added, and His-tagged proteins were bound to
nickel-nitrilotriacetic acid-agarose (Qiagen), washed, and eluted with
50 mM NaH2PO4, pH 8.0, 300 mM NaCl, and 250 mM Imidazole. Eluted proteins
were then dialyzed overnight in 50 mM Tris, pH 8.0, 50 mM NaCl, and 1 mM dithiothreitol.
His6-tagged full-length Chk2 was purified as above except
that Sarkosyl was omitted from the lysis buffer.
GST-FHA Binding Assay--
Whole cell extracts were prepared
from 293T/17 cells or HCT-15 cells expressing wild type or T68A mutant
FLAG-tagged Chk2 in NTEN buffer (150 mM NaCl, 20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.5% Nonidet
P-40, 1 mM NaF, 1 mM
Na3VO4, and protease inhibitors). One mg of
whole cell extract was incubated with 5 µg of GST-FHA pre-bound to
glutathione-agarose for 2 h at 4 °C. Bound fractions were
washed three times with NTEN buffer and then analyzed by SDS-PAGE.
Peptide Binding Assay--
ETVST(-PO4)QELYS
(Thr(P)-68) and ETVSTQELYS (Thr-68) peptides were synthesized and
conjugated to Sepharose at a concentration of 15 µmol of peptide/g
(Hartwell Center for Bioinformatics and Biotechnology at St. Jude
Children's Research Hospital). E. coli expressing GST,
GST-FHA, or GST-FHA containing the N166A mutation (GST-N166A) was lysed
in STE buffer containing 2% Triton X-100, protease inhibitors, and 1 mM dithiothreitol. Four mg of each lysate was incubated
with 25 µl of Thr-68 or Thr(P)-68-Sepharose at 4 °C for 2 h.
Mammalian whole cell extracts were prepared in NTEN buffer as above.
One mg of each extract was incubated with peptide beads for 2 h at
4 °C. The bound fraction of each extract was washed three times with
STE (E. coli) or NTEN (mammalian) buffer and then analyzed
by SDS-PAGE.
In Vitro Kinase Assay--
Reactions were performed in kinase
buffer (10 mM Hepes, pH 7.5, 10 mM
MgCl2, 0.5 mM EGTA, 10 µM ATP, 1 mM dithiothreitol, and 10 µCi of
[ Immunoprecipitation Assays--
293T/17 cells were transiently
co-transfected with SG5 FLAG- and Myc-tagged Chk2 constructs (18) using
LipofectAMINE reagent (Invitrogen). Thirty six hours after
transfection, cells were exposed to 0 or 10 Gy IR, harvested 30 min
later, and then lysed in NTEN buffer. Extracts were clarified by
centrifugation at 14,000 rpm for 20 min at 4 °C, and soluble
fractions were collected and diluted with an equal volume of 20 mM Tris-Cl, pH 8.0, and 1 mM EDTA. One mg of
diluted whole cell extract was incubated with anti-FLAG (M2)-agarose
(Sigma) or 10 µg of anti-Myc antibody plus 25 µl of protein
A/G-agarose (Oncogene) for 2 h at 4 °C. Immunoprecipitated proteins were washed with 0.5× NTEN buffer and then analyzed by SDS-PAGE.
The FHA Domain of Chk2 Is Necessary for Efficient
Autophosphorylation in Response to IR but Not Necessary for Thr-68
Phosphorylation--
A series of individual mutations within the FHA
domain were generated to determine the role of this domain in
IR-induced autophosphorylation of Chk2. The crystal structure of the
first FHA domain of RAD53 bound to a phosphothreonine-containing
peptide reveals that this complex consists of a multiple strand
To determine whether mutations expected to disrupt phosphopeptide
binding by the Chk2 FHA domain alter Chk2 activation by IR, we infected
HCT-15 cells with retrovirus encoding various FLAG-tagged mutant
cDNAs of Chk2. This cell line was chosen because endogenous Chk2
levels and activity are undetectable, and HCT-15 cells do not display
normal Chk2 function (9, 27). FLAG-tagged wild type Chk2 protein
exhibited the characteristic phosphorylation-dependent mobility shift upon SDS-PAGE that correlates with kinase activation following DNA damage (1, 2) (Fig. 1B). Consistent with
previous reports (16-18, 27), the T68A mutant was defective in this
response, and the LFS-associated I157T mutant was hyperphosphorylated
just as efficiently as wild type Chk2. Mutation of the highly conserved Arg-117, Ser-140, or Asn-166 residue to alanine was the most disruptive to DNA damage-induced phosphorylation of Chk2, whereas mutation of the
less conserved Lys-141 residue to alanine had the least impact. All
mutants were phosphorylated on Thr-68 suggesting that the integrity of
the FHA domain is not necessary for ATM-dependent phosphorylation of Chk2. These observations contrast those observed for
the unstable R145W mutant (19, 27). Interestingly, the catalytic
inactive (kd) Chk2 protein containing the D368N mutation did not
exhibit a mobility shift even though it showed strong Thr-68
phosphorylation after DNA damage. Therefore, changes in mobility of
Chk2 protein during SDS-PAGE are caused by additional phosphorylation
events that depend upon intrinsic kinase activity and an intact FHA
domain but is independent of Thr-68 phosphorylation.
In budding yeast, the FHA2 domain of RAD53 interacts with RAD9 in both
a DNA damage- and phosphorylation-dependent manner, and
this interaction facilitates trans-autophosphorylation and activation
of RAD53 (21, 25). Like RAD9, mammalian BRCA1 and 53BP1 contain
carboxyl-terminal tandem BRCT (BRCA1 carboxyl
terminus) motifs, and it has been speculated that either
protein could be a functional homologue of RAD9 (29). Of interest, both
BRCA1 and 53BP1 can associate with and/or co-localize with Chk2 and therefore may facilitate Chk2 activation by serving as a scaffold for
Chk2 trans-autophosphorylation (8, 30). Cells expressing mutant BRCA1
(HCC1937 (31)) efficiently activated Chk2 in response to IR (data not
shown) establishing that BRCA1 is not required for IR-induced
activation of Chk2. Furthermore, our attempts to determine whether Chk2
and 53BP1 directly interact through co-immunoprecipitation studies were
unsuccessful (53BP1 reagents were kindly provided by J. Chen).
Therefore, other BRCA1- and 53BP1-independent mechanisms may exist that
facilitate Chk2 autophosphorylation in irradiated cells.
Chk2 Specifically Interacts with Its Own FHA Domain following
Modification by DNA Damage--
We considered the possibility that
autophosphorylation is facilitated through direct oligomerization of
Chk2 which is dependent upon both Thr-68 phosphorylation and a
functional FHA domain. Binding assays were performed using recombinant
GST protein fused to the Chk2 FHA domain (GST-FHA) as bait and whole
cell extracts for a source of Chk2 protein to determine whether Chk2
directly interacts with its own FHA domain. Chk2 protein present in
whole cell extract prepared from irradiated cells specifically bound to
GST-FHA immobilized on glutathione-agarose (Fig.
2A). The interaction between
Chk2 and GST-FHA was decreased if extract made from irradiated cells
was pretreated with A Peptide Representing the Phosphothreonine 68 Region of Chk2 Is a
Ligand for the Chk2 FHA Domain--
Thr-68 phosphorylation by ATM is
believed to be the first event in the pathway leading to full
activation of Chk2 in irradiated cells. To determine whether Thr-68
phosphorylation was required for Chk2 binding to GST-FHA, we prepared
whole cell extracts from HCT15 cells expressing FLAG-tagged wild type
or T68A Chk2 protein and subjected them to the in vitro
GST-FHA binding assay. T68A mutant Chk2 protein present in irradiated
cells failed to interact with GST-FHA suggesting that phosphorylation
of Thr-68 is necessary for this DNA damage-dependent
interaction (Fig. 2C). To confirm that the FHA domain of
Chk2 can specifically bind to Thr(P)-68 Chk2, additional binding assays
were performed using extracts made from E. coli expressing
GST, GST-FHA, and GST-N166A and a 10-amino acid peptide representing
the Thr-68 region of Chk2 conjugated to Sepharose. Only peptide
containing Thr(P)-68 bound GST-FHA, and as expected, the N166A FHA
domain mutant did not bind to Thr(P)-68 peptide-Sepharose
(Fig. 3A). Therefore, a
peptide consisting of the Thr(P)-68 region of Chk2 is a
phospho-specific ligand for the Chk2 FHA domain, and the N166A
mutation disrupts Chk2 FHA domain function without negatively
affecting the stability of the protein.
Mutations within the FHA domain that alter efficient activation of Chk2
in irradiated cells (R117A, S140A, K141A, and N166A) significantly
reduced the ability of Chk2 to bind to Thr(P)-68 peptide in
vitro (Fig. 3B). Consistent with its ability to be efficiently autophosphorylated and activated following IR, the I157T
mutant bound to Thr(P)-68 peptide as well as wild type (Fig. 3B). Therefore, the efficiency by which Chk2 is
autophosphorylated in response to IR grossly correlates with whether
Chk2 can bind to P-Thr-68 peptide via the FHA domain. To determine
whether the interaction between Thr(P)-68 and Chk2 depends upon a
modification induced by IR, 293T/17 cells were irradiated or
mock-irradiated, and whole cell extracts were incubated with either
Thr-68 or Thr(P)-68 peptide-Sepharose. Chk2 from control rather than
irradiated cell extracts bound to Thr(P)-68 peptide-Sepharose
suggesting that the affinity of the FHA domain is reduced after cells
are exposed to IR (Fig. 3C). Thus, the interaction between
Thr(P)-68 peptide and full-length Chk2 depends upon an intact FHA
domain but is diminished when Chk2 is modified in DNA-damaged cells.
Chk2 Phosphorylates Its Own FHA Domain in Vitro Resulting in
Reduced Affinity for Thr(P)-68 Peptide--
DNA
damage-dependent phosphorylation of the Chk2 FHA domain may
be one mechanism by which Chk2 binding to Thr(P)-68 peptide is reduced.
To explore the possibility that Chk2 autophosphorylates within the
FHA domain or other potential sites, we purified three different
recombinant Chk2 fragments that together represent the entire Chk2
protein molecule and subjected each fragment to in vitro
kinase assays using purified wt or kd Chk2 kinase. Consistent with Chk2
autophosphorylating the activation segment, recombinant wt Chk2
phosphorylated a catalytic inactive kinase domain fragment (Fig.
4A). The FHA domain was highly
phosphorylated by wt Chk2, whereas the SQ/TQ-rich region of Chk2 does
not appear to be a substrate for Chk2 phosphorylation in
vitro (Fig. 4A). Phosphorylation of GST-FHA by wt Chk2
also reduced its ability to bind to Thr(P)-68-Sepharose and to interact
with endogenous Chk2 present in extract obtained from DNA-damaged cells
(Fig 4, B and C). Therefore, autophosphorylation within the FHA domain of Chk2 may induce rapid dissociation of Chk2
oligomers. It is unclear whether the FHA domain of Chk2 is required for
interactions with the proteins it targets for phosphorylation. If this
proves to be the case, autophosphorylation within the FHA domain may
selectively affect Thr(P)-68 Chk2 binding and not all phosphoprotein
interactions.
Catalytic Inactive Chk2 Forms an Oligomer in Vivo--
FLAG-tagged
and Myc-tagged catalytic inactive (kd) Chk2 proteins were co-expressed
in 293T/17 cells to determine whether two or more Chk2 proteins
associate with one another in vivo and whether Thr-68
phosphorylation and FHA domain integrity are required for this
interaction. By using this approach, we have found that kd Chk2 forms a
stable oligomer in 293T/17 cells based on the observation that both the
FLAG and Myc antibodies can co-immunoprecipitate epitope-tagged Chk2
(Fig. 5). Despite DNA damage-induced
Thr-68 phosphorylation of the N166A/kd double mutant, we were unable to
detect oligomer formation by this mutant in irradiated cells suggesting
that the integrity of the FHA domain is important for oligomer
formation. Oligomer formation by the T68A/kd mutant is also deficient
as compared with that exhibited by the kd Chk2 proteins (Fig. 5).
Therefore, stable oligomer formation by catalytic inactive Chk2
requires both Thr-68 phosphorylation and an intact FHA domain.
Repeated attempts to co-immunoprecipitate two differentially tagged
wild type Chk2 molecules using this approach have been unsuccessful
(data not shown). The observation that only kd Chk2 formed oligomers
suggests that autophosphorylation by Chk2 reduces the affinity of one
Chk2 molecule for another. We have frequently found that transient
overexpression of wild type Chk2 at high levels in 293T/17 cells is
associated with Chk2 autophosphorylation and activation in the absence
of DNA damage (data not shown). This phenomenon is analogous to what
occurs when RAD53 is expressed at high concentrations in E. coli where it becomes hyperphosphorylated in the absence of
RAD9 (25). Therefore, the inability to co-immunoprecipitate differentially tagged, wild type Chk2 proteins may be due to the fact
that Chk2 is already activated and can no longer form stable oligomers
once autophosphorylation occurs. This is consistent with our findings
that recombinant GST-FHA phosphorylated by Chk2 in vitro
exhibits reduced affinity for the Thr(P)-68 region of Chk2 and modified
Chk2 expressed in irradiated cells (Fig. 4).
In addition to wild type Chk2 activated in a DNA damage-independent
manner upon overexpression in 293T/17 cells, we have also observed high
levels of constitutive Thr-68 phosphorylation of kd Chk2 under similar
conditions (Fig. 5). High levels of Thr-68 phosphorylation may reflect
an inability of a specific phosphatase to gain access to
Thr-68-phosphorylated kd Chk2 because it is presumably shielded by the
FHA domain. The fact that we have only been able to
co-immunoprecipitate kd Chk2 suggests that once phosphorylated on
Thr-68, oligomerization of kd Chk2 becomes very stable. This is most
likely due to low autophosphorylation activity expressed by kd Chk2
that would in turn result in a lower dissociation rate of the oligomer complex.
Thus far, this is the first biologically relevant
phosphorylation-dependent ligand described for the FHA
domain of Chk2. Together, these data support the model that
phosphorylation of Thr-68 by ATM promotes binding of the SQ/TQ region
of one Chk2 molecule to the FHA domain of another forming oligomers.
Oligomerization may effectively increase the local concentration of
Chk2 such that trans-autophosphorylation becomes more favorable (Fig.
6). Trans-autophosphorylation within the
FHA domain may then cause dissociation of the Chk2 complex. Active Chk2
monomers are released and proceed to phosphorylate effector molecules
important for mammalian checkpoint control.
We thank Jing Wu for excellent technical
assistance with retrovirus production, Elio Vanin for the pEQPAM3
retrovirus packaging construct, and Risa Kitagawa for critical reading
of this manuscript.
Similar work is described in Xu, X.,
Tsvetko, L. M., and Stern, D. F. (2002) Mol. Cell.
Biol., in press.
*
This work was supported by National Institutes of Health
Grant CA86861 and by the American Lebanese Syrian Associated Charities of the St. Jude Children's Research Hospital.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Pfizer Global
Research and Development, 2800 Plymouth Rd., Ann Arbor,
MI 48105. Tel.: 734-622-4106; Fax: 734-622-7158; E-mail:
Christine. Canman{at}Pfizer.com.
Published, JBC Papers in Press, March 18, 2002, DOI 10.1074/jbc.M200822200
The abbreviations used are:
ATM, ataxia
telangiectasia-mutated;
IR, ionizing radiation;
FHA, forkhead-associated;
LFS, Li-Fraumeni syndrome;
GST, glutathione
S-transferase;
wt, wild type;
kd, kinase-dead;
Gy, gray.
Phosphorylation of Threonine 68 Promotes Oligomerization and
Autophosphorylation of the Chk2 Protein Kinase via the
Forkhead-associated Domain*
,
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
-32P]ATP) for 30 min at 30 °C and contained 1 µg
of purified His-tagged wild type (wt) or catalytic inactive (kd) Chk2
plus 2 µg of purified protein substrates. Kinase reactions were then
subjected to 10% SDS-PAGE and transferred to nitrocellulose.
Radiolabeled proteins were detected by PhosphorImager analysis
(Molecular Dynamics). For binding assays using Chk2-phosphorylated
GST-FHA, 10 µg of GST-FHA bound to glutathione-agarose was incubated
with wt or kd Chk2 in the same buffer without
[
-32P]ATP for 30 min at 30 °C. Bound GST-FHA was
washed three times with NTEN buffer and once with NTEN buffer
containing 500 mM LiCl. One-half of each sample was
directly used for the GST-FHA binding assay, whereas the other half was
eluted with 10 mM glutathionine and used for the peptide
binding assay. Both assays were performed as described above.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
-sandwich containing short
-helical loops that extend out and
make contact with a phosphothreonine-containing peptide (24). These
structural data were used to produce a modified sequence alignment of
several FHA domains including Chk2 (24). Based on this information, we
created mutations at conserved residues that are located within the
-sandwich (G116E, H143A, and R145W) or proposed
-helical loops
that are expected to make contact with a phosphopeptide ligand (R117A,
S140A, K141A, N166A, and I157T) (Fig.
1A). Mutations of residues
believed to form the
-sandwich structure of the Chk2 FHA domain
(G116E and H143A) appeared to destabilize the protein (data not shown).
These results are similar to what has already been documented for the
LFS-associated R145W (10, 26, 27) and suggest that mutations located
within the
-sandwich are likely to destabilize Chk2 protein.
Mutations within the
-helical loops did not affect protein
stability, and these Chk2 mutants were therefore used for further
investigation.

View larger version (28K):
[in a new window]
Fig. 1.
Mutations within the proposed
phosphopeptide-binding region of the Chk2 FHA domain prevent efficient
activation of Chk2. A, sequence alignment of the FHA domains
found in S. pombe Cds1 (SpCds1), S. cerevisiae RAD53 (ScRad53) (FHA1), and Homo
sapiens Chk2 (HsChk2). NCBI Protein Database
accession numbers for protein sequences used in the alignment
are as follows: gi:12644396, gi:134835, and gi:6005850, respectively.
Residues believed to participate in
-loop or
-sheet secondary
structure are highlighted above the alignment (24).
Arrows indicate the positions of sites mutated within the
Chk2 FHA domain. B, HCT-15 cells expressing wild type
(wt) or mutant Chk2 proteins were exposed to 0 or 6 Gy IR
and incubated for 30 min. Whole cell extracts were prepared and
separated by SDS-PAGE. Immunoblots were probed with either anti-FLAG
monoclonal antibody (top panel) or anti-phosphothreonine 68 (P-T68) rabbit polyclonal antibodies (bottom
panel).
protein phosphatase consistent with the
findings that protein interactions with FHA domains are
phosphorylation-dependent (23) (Fig. 2A).
Therefore, binding of Chk2 from irradiated cells to GST-FHA required
DNA damage-induced phosphorylation in addition to a functional FHA
domain because mutating a highly conserved residue within the FHA
domain of Chk2 (GST-N166A) abolished specific binding of Chk2 obtained
from irradiated cells (Fig. 2B).

View larger version (22K):
[in a new window]
Fig. 2.
A purified recombinant Chk2 FHA domain
interacts with Chk2 protein in a phosphorylation-dependent
manner. A, whole cell extracts of 293T/17 cells were
prepared 30 min after exposure to 0 or 6 Gy IR. One-half of the extract
isolated from irradiated cells was treated with
protein phosphatase
(PPase). Equivalent amounts of each extract were then
incubated with purified GST-FHA protein bound to glutathione-agarose
beads, washed, separated by SDS-PAGE, and transferred to
nitrocellulose. Whole cell extracts (top panel) or the
GST-FHA bound fraction of each extract (middle panel) was
immunoblotted with anti-Chk2 antibodies. Equivalent amounts of GST-FHA
protein in each lane were verified by immunoblotting with anti-GST
(bottom panel). B, whole cell (WCE)
were incubated with GST, GST-FHA, or GST-FHA containing the N166A
mutation (GST-N166A) as above. Whole cell extracts or Chk2 bound to
various GST fusion proteins were immunoblotted with anti-Chk2. The
lower right panel shows the total amount of GST fusion
protein subjected to each binding reaction as determined by fast green
staining of nitrocellulose membrane. C, HCT-15 cells
expressing wild type (wt) or T68A FLAG-tagged Chk2 protein
were exposed to 0 or 6 Gy IR, harvested 30 min later, and used for the
GST-FHA pulldown assay as in A. A fraction of each WCE was
immunoblotted with either anti-FLAG or anti-Thr(P)-68 (top
panels). Bound fractions were immunoblotted with either anti-FLAG
or anti-GST (bottom panels).

View larger version (34K):
[in a new window]
Fig. 3.
The FHA domain of Chk2 interacts with a
peptide representing the Thr-68 region of Chk2 in a Thr-68
phosphorylation-dependent manner. A, E. coli extracts expressing GST, GST-FHA, or GST-FHA-N166A protein
(GST immunoblot shown in left panel) were incubated with
Thr-68 peptide or phosphothreonine 68 (P-T68) peptide
conjugated to Sepharose. Bound fractions were washed, separated by
SDS-PAGE, and transferred to nitrocellulose. The
Thr(P)-68-peptide-Sepharose interacting proteins were visualized by
fast green staining of nitrocellulose membrane (right
panel). The two bands migrating faster than GST-FHA and GST-N166A
represent degradation products that are reactive with the GST antibody.
B, HCT-15 cells expressing different FLAG-tagged mutant Chk2
protein were incubated with Thr(P)-68 peptide-Sepharose. Whole cell
extracts (WCE) or Thr(P)-68 peptide bound fractions were
separated by SDS-PAGE and immunoblotted with anti-FLAG. C,
whole cell extracts from 293T/17 cells exposed to 0 or 6 Gy IR were
used for the peptide-Sepharose binding assay. Bound fractions were
immunoblotted with anti-Chk2.

View larger version (28K):
[in a new window]
Fig. 4.
Chk2 autophosphorylates its own FHA domain
thereby reducing its interaction with Thr(P)-68. A, GST or
His-tagged recombinant proteins consisting of the SQ/TQ-rich region
(F1), the FHA domain (F2), or a catalytic inactive (kd) kinase domain
(F3) of Chk2 were expressed in E. coli and purified.
Recombinant full-length wild type (wt) and kd Chk2 proteins
prepared from E. coli were subjected to an in
vitro kinase assay using the various domains (F1-3) of
Chk2 as substrates. Samples were separated by SDS-PAGE and transferred
to nitrocellulose, and the amounts of phosphorylation of Chk2 itself
(top left panel) and substrates (bottom left
panel) were visualized by PhosphorImaging (32P
incorporation). Total amounts of recombinant kd and wt Chk2 proteins
(top right panel) or substrate Chk2 domain proteins
(bottom right panel) contained in each assay were determined
by fast green staining of nitrocellulose membrane. a.a.,
amino acids. B, purified GST-FHA protein was preincubated
with either purified wt or kd Chk2 in the presence of
Mg2+ATP. Chk2-phosphorylated GST-FHA proteins were then
mixed with Thr(P)-68 peptide-Sepharose, and bound fractions were probed
with anti-GST antibody after SDS-PAGE and transfer to nitrocellulose.
C, whole cell extracts from 293T/17 cells were prepared
after 6 Gy of ionizing radiation. GST-FHA protein was bound to
glutathione-agarose, preincubated with Mg2+ATP and either
wt or kd recombinant Chk2, and then mixed with cell extract. Bound
fractions were separated by SDS-PAGE, transferred to nitrocellulose,
and immunoblotted with anti-Chk2.

View larger version (74K):
[in a new window]
Fig. 5.
Stable oligomer formation by catalytic
inactive Chk2 requires both Thr-68 phosphorylation and an intact FHA
domain. 293T/17 cells were transiently co-transfected with
constructs encoding FLAG and Myc-tagged catalytic inactive (kd),
T68A/kd, or N166A/kd Chk2. Cells were exposed to 0 or 10 Gy IR and
harvested 30 min later. Whole cell extracts (WCE) were
divided in half and then subjected to immunoprecipitation
(IP) with either anti-FLAG or Myc monoclonal antibodies.
Immunoprecipitates were resolved by SDS-PAGE and immunoblotted with
anti-FLAG or anti-Myc as indicated (bottom four panels).
Anti-FLAG, anti-Myc, and anti-Thr(P)-68 immunoblots of whole cell
extracts used for the immunoprecipitation assay are shown in the
top three panels.

View larger version (25K):
[in a new window]
Fig. 6.
A model of Chk2 activation in irradiated
cells. In response to IR, ATM targets Thr-68 within the SQ/TQ-rich
domain of Chk2. Thr-68-phosphorylated Chk2 proteins form an oligomer
through interactions between the phosphothreonine 68 region of one Chk2
molecule and the FHA domain of another. Chk2 proteins then
trans-autophosphorylate at multiple sites including the FHA domain and
activation segment within the kinase domain. Phosphorylation of an
unknown site(s) within the FHA domain causes oligomer dissociation
resulting in the release of fully active, hyperphosphorylated Chk2
monomers.
![]()
ACKNOWLEDGEMENTS
![]()
Note Added in Proof
![]()
FOOTNOTES
Both authors contributed equally to this work.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
1.
Matsuoka, S.,
Huang, M.,
and Elledge, S. J.
(1998)
Science
282,
1893-1897 2.
Brown, A. L.,
Lee, C.-H.,
Schwarz, J. K.,
Mitiku, N.,
Piwnica-Worms, H.,
and Chung, J. H.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
3745-3750 3.
Blasina, A.,
Van de Weyer, I.,
Laus, M. C.,
Luyten, W. H. M. L.,
Parker, A. E.,
and McGowan, C. H.
(1999)
Curr. Biol.
9,
1-10[CrossRef][Medline]
[Order article via Infotrieve]
4.
Chaturvedi, P.,
Eng, W. K.,
Zhu, Y.,
Mattern, M. R.,
Mishra, R.,
Hurle, M. R.,
Zhang, X.,
Annan, R. S., Lu, Q.,
Faucette, L. F.,
Scott, G. F., Li, S.,
Carr, S. A.,
Johnson, R. K.,
Winkler, J. D.,
and Zhou, B.-B. S.
(1999)
Oncogene
18,
4047-4054[CrossRef][Medline]
[Order article via Infotrieve]
5.
Chehab, N. H.,
Malikzay, A.,
Appel, M.,
and Halazonetis, T. D.
(2000)
Genes Dev.
14,
278-288 6.
Shieh, S.-Y.,
Ahn, J.,
Tamai, K.,
Taya, Y.,
and Prives, C.
(2000)
Genes Dev.
14,
289-300 7.
Hirao, A.,
Kong, Y.-Y.,
Matsuoka, S.,
Wakeham, A.,
Ruland, J.,
Yoshida, H.,
Liu, D.,
Elledge, S. J.,
and Mak, T. W.
(2000)
Science
287,
1824-1827 8.
Lee, J.-S.,
Collins, K. M.,
Brown, A. L.,
Lee, C.-H.,
and Chung, J. H.
(2000)
Nature
404,
201-204[CrossRef][Medline]
[Order article via Infotrieve]
9.
Falck, J.,
Mailand, N.,
Syljuasen, R. G.,
Bartek, J.,
and Lukas, J.
(2001)
Nature
410,
842-847[CrossRef][Medline]
[Order article via Infotrieve]
10.
Bell, D. W.,
Varley, J. M.,
Szydlo, T. E.,
Kang, D. H.,
Wahrer, D. C. R.,
Shannon, K. E.,
Lubratovich, M. L.,
Verselis, S. J.,
Isselbacher, K. J.,
Fraumeni, J. F.,
Birch, J. M., Li, F. P.,
Garber, J. E.,
and Haber, D. A.
(2000)
Science
286,
2528-2531 11.
Miller, C. W.,
Ikezoe, T.,
Krug, U.,
Hofmann, W.-K.,
Tavor, S.,
Vegesna, V.,
Tsukasaki, K.,
Takeuchi, S.,
and Koeffler, H. P.
(2002)
Genes Chromosomes Cancer
33,
17-21[CrossRef][Medline]
[Order article via Infotrieve]
12.
Vahteristo, P.,
Tamminen, A.,
Karvinen, P.,
Eerola, H.,
Eklund, C.,
Aaltonen, L. A.,
Blomqvist, C.,
Aittomaki, K.,
and Nevanlinna, H.
(2001)
Cancer Res.
61,
5718-5722 13.
Hofmann, W.-K.,
Miller, C. W.,
Tsukasaki, K.,
Tavor, S.,
Ikezoe, T.,
Hoelzer, D.,
Takeuchi, S.,
and Koeffler, H. P.
(2001)
Leuk. Res.
25,
333-338[CrossRef][Medline]
[Order article via Infotrieve]
14.
Haruki, N.,
Saito, H.,
Tatematsu, Y.,
Konishi, H.,
Harano, T.,
Masuda, A.,
Osada, H.,
Fujii, Y.,
and Takahashi, T.
(2000)
Cancer Res.
60,
4689-4692 15.
Bartek, J.,
Falck, J.,
and Lukas, J.
(2001)
Nat. Rev. Mol. Cell Biol.
2,
877-886[CrossRef][Medline]
[Order article via Infotrieve]
16.
Matsuoka, S.,
Rotman, G.,
Ogawa, A.,
Shiloh, Y.,
Tamai, K.,
and Elledge, S. J.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
10389-10394 17.
Melchionna, R.,
Chen, X.-B.,
Blasina, A.,
and McGowan, C. H.
(2000)
Nat. Cell Biol.
2,
762-765[CrossRef][Medline]
[Order article via Infotrieve]
18.
Ahn, J.-H.,
Schwarz, J. K.,
Piwnica-Worms, H.,
and Canman, C. E.
(2000)
Cancer Res.
60,
5934-5936 19.
Lee, C.-H.,
and Chung, J. H.
(2001)
J. Biol. Chem.
276,
30537-30541 20.
Johnson, L. N.,
Noble, M. E. M.,
and Owen, D. J.
(1996)
Cell
85,
149-158[CrossRef][Medline]
[Order article via Infotrieve]
21.
Sun, Z.,
Hsiao, J.,
Fay, D. S.,
and Stern, D. F.
(1998)
Science
281,
272-274 22.
Li, J.,
Smith, G. P.,
and Walker, J. C.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
7821-7826 23.
Durocher, D.,
Henkcel, J.,
Fersht, A. R.,
and Jackson, S. P.
(1999)
Mol. Cell
4,
387-394[CrossRef][Medline]
[Order article via Infotrieve]
24.
Durocher, D.,
Taylor, I. A.,
Sarbassova, D.,
Haire, L. F.,
Westcott, S. L.,
Jackson, S. P.,
Smerdon, S. J.,
and Yaffe, M. B.
(2001)
Mol. Cell
6,
1169-1182
25.
Gilbert, C. S.,
Green, C. M.,
and Lowndes, N. F.
(2001)
Mol. Cell
8,
129-136[CrossRef][Medline]
[Order article via Infotrieve]
26.
Lee, S. B.,
Kim, S. H.,
Bell, D. W.,
Wahrer, D. C. R.,
Schiripo, T. A.,
Jorczak, M. M.,
Sgroi, D. C.,
Garber, J. E., Li, F. P.,
Nichols, K. E.,
Varley, J. M.,
Godwin, A. K.,
Shannon, K. E.,
Harlow, E.,
and Haber, D. A.
(2001)
Cancer Res.
61,
8062-8067 27.
Wu, X.,
Webster, S. R.,
and Chen, J.
(2001)
J. Biol. Chem.
276,
2971-2974 28.
Graves, P. R., Yu, L.,
Schwarz, J. K.,
Gales, J.,
Sausville, E. A.,
O'Connor, P. M.,
and Piwnica-Worms, H.
(2000)
J. Biol. Chem.
275,
5600-5605 29.
Zhou, B.-B. S.,
and Elledge, S. J.
(2000)
Nature
408,
433-439[CrossRef][Medline]
[Order article via Infotrieve]
30.
Ward, I. M., Wu, X.,
and Chen, J.
(2001)
J. Biol. Chem.
276,
47755-47758 31.
Tomlinson, G. E.,
Chen, T. T.,
Stastny, V. A.,
Virmani, A. K.,
Spillman, M. A.,
Tonk, V.,
Schneider, N. R.,
Wistuba, I. I.,
Shay, J. W.,
Minna, J. D.,
and Gazdar, A. F.
(1998)
Cancer Res.
58,
3237-3242
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
C. M. Lovly, L. Yan, C. E. Ryan, S. Takada, and H. Piwnica-Worms Regulation of Chk2 Ubiquitination and Signaling through Autophosphorylation of Serine 379 Mol. Cell. Biol., October 1, 2008; 28(19): 5874 - 5885. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Kass, J. Ahn, T. Tanaka, W. A. Freed-Pastor, S. Keezer, and C. Prives Stability of Checkpoint Kinase 2 Is Regulated via Phosphorylation at Serine 456 J. Biol. Chem., October 12, 2007; 282(41): 30311 - 30321. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Rao, C. Conti, J. Guirouilh-Barbat, A. Nakamura, Z.-H. Miao, S. L. Davies, B. Sacca, I. D. Hickson, A. Bensimon, and Y. Pommier Endogenous {gamma}-H2AX-ATM-Chk2 Checkpoint Activation in Bloom's Syndrome Helicase Deficient Cells Is Related to DNA Replication Arrested Forks Mol. Cancer Res., July 1, 2007; 5(7): 713 - 724. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Henderson, M. A. Munoz, D. N. Saunders, J. L. Clancy, A. J. Russell, B. Williams, D. Pappin, K. K. Khanna, S. P. Jackson, R. L. Sutherland, et al. EDD Mediates DNA Damage-induced Activation of CHK2 J. Biol. Chem., December 29, 2006; 281(52): 39990 - 40000. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Buscemi, L. Carlessi, L. Zannini, S. Lisanti, E. Fontanella, S. Canevari, and D. Delia DNA Damage-Induced Cell Cycle Regulation and Function of Novel Chk2 Phosphoresidues Mol. Cell. Biol., November 1, 2006; 26(21): 7832 - 7845. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sodha, T. S. Mantoni, S. V. Tavtigian, R. Eeles, and M. D. Garrett Rare Germ Line CHEK2 Variants Identified in Breast Cancer Families Encode Proteins That Show Impaired Activation. Cancer Res., September 15, 2006; 66(18): 8966 - 8970. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Yoda, X. Z. Xu, N. Onishi, K. Toyoshima, H. Fujimoto, N. Kato, I. Oishi, T. Kondo, and Y. Minami Intrinsic Kinase Activity and SQ/TQ Domain of Chk2 Kinase as Well as N-terminal Domain of Wip1 Phosphatase Are Required for Regulation of Chk2 by Wip1 J. Biol. Chem., August 25, 2006; 281(34): 24847 - 24862. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-j. Xu, M. Davenport, and T. J. Kelly Two-stage mechanism for activation of the DNA replication checkpoint kinase Cds1 in fission yeast Genes & Dev., April 15, 2006; 20(8): 990 - 1003. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li and D. F. Stern DNA Damage Regulates Chk2 Association with Chromatin J. Biol. Chem., November 11, 2005; 280(45): 37948 - 37956. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li and D. F. Stern Regulation of CHK2 by DNA-dependent Protein Kinase J. Biol. Chem., March 25, 2005; 280(12): 12041 - 12050. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Wei, Y.-F. Chou, Y.-H. Ou, Y.-H. Yeh, S.-W. Tyan, T.-P. Sun, C.-Y. Shen, and S.-Y. Shieh TTK/hMps1 Participates in the Regulation of DNA Damage Checkpoint Response by Phosphorylating CHK2 on Threonine 68 J. Biol. Chem., March 4, 2005; 280(9): 7748 - 7757. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. McSherry and P. R. Mueller Xenopus Cds1 Is Regulated by DNA-Dependent Protein Kinase and ATR during the Cell Cycle Checkpoint Response to Double-Stranded DNA Ends Mol. Cell. Biol., November 15, 2004; 24(22): 9968 - 9985. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Tosti, L. Waldbaum, G. Warshaw, E. A. Gross, and R. Ruggieri The Stress Kinase MRK Contributes to Regulation of DNA Damage Checkpoints through a p38{gamma}-independent Pathway J. Biol. Chem., November 12, 2004; 279(46): 47652 - 47660. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Pike, N. Tenis, and J. Heierhorst Rad53 Kinase Activation-independent Replication Checkpoint Function of the N-terminal Forkhead-associated (FHA1) Domain J. Biol. Chem., September 17, 2004; 279(38): 39636 - 39644. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Cerosaletti and P. Concannon Independent Roles for Nibrin and Mre11-Rad50 in the Activation and Function of Atm J. Biol. Chem., September 10, 2004; 279(37): 38813 - 38819. [Abstract] [Full Text] [PDF] |
||||
|
|